Bioventus Stock

Bioventus FCF Conversion

The FCF Conversion Rate (FCF/EBITDA) of Bioventus (BVS) as of Aug 12, 2026 is 314.16 %. In the previous year, FCF Conversion Rate (FCF/EBITDA) was -112.66 % — a change of -378.85% (higher).

FCF Conversion

314.16 %

YoY

-378.85%

Last updated:

FCF Conversion Rate (FCF/EBITDA) of Bioventus is 2026 314.16 % . FCF Conversion Rate (FCF/EBITDA) of Bioventus was 2025 -112.66 % . It decreases by -378.85% higher compared to the previous year.
Access this data via the Eulerpool API

Bioventus Stock analysis

What does Bioventus do? Bioventus Inc. is a company specializing in the development, manufacture, and marketing of biological solutions for patients with bone and joint problems. It was founded in 2012 by a group of orthopedic specialists and venture capital investors. The company is headquartered in Durham, North Carolina, USA and is a leading provider of clinically proven biological solutions for patients with orthopedic conditions. Bioventus works closely with orthopedic surgeons and hospitals to ensure its products meet the needs of patients. Its portfolio includes orthobiologics, bone healing, and surgical products. Some of its notable products include Gel-One® Cross-Linked Hyaluronic Acid for osteoarthritis treatment, EXOGEN® Ultrasound Bone Healing System for improving bone healing, and BONESUPPORT® Cerament® bone void filler for bone regeneration. Bioventus is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Bioventus stock

FCF Conversion Rate (FCF/EBITDA) of Bioventus is 314.16 % in 2026.

FCF Conversion Rate (FCF/EBITDA) of Bioventus changed from -112.66 % to 314.16 %, representing a -378.85% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of FCF Conversion Rate (FCF/EBITDA) Bioventus since 2006 – with annual values, charts, and detailed analysis.

FCF conversion measures how effectively EBITDA converts to free cash flow. Higher conversion indicates efficient capital allocation and low maintenance costs.

A 'good' varies by industry and company stage. On Eulerpool, you can compare FCF Conversion Rate (FCF/EBITDA)'s Bioventus with sector peers and the industry average to assess whether it is attractive.

To evaluate FCF Conversion Rate (FCF/EBITDA)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for FCF Conversion Rate (FCF/EBITDA).

Access this data via the Eulerpool API

Cash Flow — Bioventus

All Key Metrics — Bioventus